The Persistent corneal epithelial defects treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing at a CAGR of 4.6% in the forecast period of 2020 to 2027and expected to reach USD 504.86 million by 2027 from USD 355.40 million in 2019. Increasing concern about Persistent corneal epithelial defects treatment is increasing usage of device and medications for persistent corneal epithelial defects treatment which is the factor for the market growth.
North America Persistent Corneal Epithelial Defects Treatment Market Scope and Market Size: -
On the basis of type, the market is segmented into devices and medication. Although lubricant eye drops are the first line treatment for the PCED treatment, are generally insufficient to treat PCED. PCEDs and low price of the device as compared to alternative treatment options.
On the basis of end user, the market is segmented into hospitals, homecare, specialty clinics and others. Hospital segment is dominating the persistent corneal epithelial defects treatment market because of the high patient volume and high treatment rates.
On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
North America Persistent Corneal Epithelial Defects Treatment Market Country Level Analysis: -
The North America market is analysed and market size information is provided by country by clinical causes, type, end user and distribution channel as referenced above.
North America persistent corneal epithelial defects treatment market is growing due to increase in mechanical traumas cases are expected to grow at the significant growth rate in the forecast period of 2020 to 2027.
Competitive Landscape and North America Persistent Corneal Epithelial Defects Treatment Market Share Analysis: -
The major players covered in the report are Dompé Farmaceutici S.p.A, Novartis AG, Allergan, Katena Products. Inc., Johnson Johnson Services, Inc., Hunt Valley PharmaLAB, Laboratoires THEA S.A.S, Skye Biologics Inc., I-MED Pharma inc., Almirall, S.A, Ocular Science, Inc., Kala Pharmaceuticals, Bausch Health, Integra LifeSciences Corporation, BioTissue (A Subsidiary of TissueTech, Inc.) among other players domestic and global. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
In October 2017, Bio-Tissue entered in strategic agreement with Optima Pharmazeutische GmbH, a pharmaceutical company that offers ophthalmology, otorhinolaryngology and pneumology products. This agreement helps Bio-Tissue to distribute its Natural Ocular Cleanser in Germany.
MAJOR TOC OF THE REPORT: -
- Chapter One: Introduction
- Chapter Two: Market Analysis and Insights
- Chapter Three: Market Dynamics
- Chapter Four: Market Scope
- Chapter Five: Market Regional Insights
- Chapter Six: Competitive Landscape System Market
Browse Related Reports: -
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Data Bridge Market Research